Qualitative Concept
Boehringer Ingelheim’s Nerandomilast Succeeds in Second Phase III Lung Fibrosis Trial, Paving Way for FDA Approval
Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive fibrosing interstitial lung diseases (PF-ILDs), lung function improvement, FDA approval, phosphodiesterase 4B (PDE4B) inhibitor
Fourth Patient Receives Gene-Edited Pig Kidney in Groundbreaking Clinical Trial
xenotransplantation, clinical trial, gene-edited pig kidney, FDA approval, United Therapeutics, eGenesis, end-stage renal disease, organ shortage
Congressional Healthcare Reform Priorities Under Trump’s Second Term
ACA repeal, Medicaid block grants, price transparency, Medicare Advantage, drug pricing, value-based care
FDA Approves Onapgo: Breakthrough Infusion Device for Advanced Parkinson’s Disease
Onapgo, apomorphine hydrochloride, Parkinson’s disease, subcutaneous infusion, motor fluctuations, FDA approval, Supernus Pharmaceuticals
FDA Approves Roche’s Susvimo for Diabetic Macular Edema: A Breakthrough in Continuous Delivery Eye Treatment
Susvimo, ranibizumab, diabetic macular edema, DME, Roche, FDA approval, continuous delivery, eye implant, vision improvement
RFK Jr. Dodges Vaccine-Autism Questions in Senate Confirmation Responses
Robert F. Kennedy Jr., HHS Secretary nomination, vaccine misinformation, autism, Senate confirmation hearings, written responses
FDA Approves Vertex’s Journavx: First Non-Opioid Pain Medication in Decades
Journavx, suzetrigine, non-opioid, acute pain, FDA approval, Vertex Pharmaceuticals, pain management, opioid alternative
World Cancer Day 2025: Innovations in Prevention, Detection, and Treatment
cancer research, immunotherapy, early detection, AI in oncology, novel therapies, clinical trials, personalized medicine
Pharmaceutical Industry Warns of Drug Shortages and Price Hikes Due to Trump’s New Tariffs
Trump tariffs, drug shortages, price increases, pharmaceutical industry, trade groups, supply chain disruption, generic drugs, active pharmaceutical ingredients (APIs)
FDA Approves Roche’s PATHWAY HER2 Test for HER2-Ultralow Metastatic Breast Cancer
Roche, PATHWAY HER2 (4B5) test, FDA approval, HER2-ultralow, metastatic breast cancer, companion diagnostic, Enhertu, personalized medicine